Conference reports

Wide disparity in switch to second-line therapy among children in CHIPS cohort

Explanation for failure of TMC-125 (etravirine) in TMC227 study

Saquinavir/r vs lopinavir/r: interim results from the Gemini study

d4T associated with significantly increased risk of type-2 diabetes mellitus

Drug interactions with darunavir (TMC-114)

Drug interactions with etravirine (TMC-125)

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

Community meeting on criminalisation of HIV transmission: jailing people for passing on HIV may threaten public health

8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 September 2006, San Francisco

The role of the metabolic syndrome in HIV

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

Leptin reduces visceral abdominal tissue (VAT) without reducing limb fat

Adipose tissue morphology improved after treatment discontinuation

Incidence of lipodystrophy in Rwanda

46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco

MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results

Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients

Cell studies predict cross-resistance among integrase inhibitors

HIV may use different coreceptors in blood and brain

Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives

NRTI elvucitabine active against HIV in a 7-day monotherapy study

Efavirenz/tenofovir fails as 2-drug maintenance regimen

Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees

Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London

Further reports from XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada

Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV positive women in Lusaka, Zambia

Effect of herpes simplex therapy on genital and plasma HIV viral load

Maternal health and prevention of mother to child transmission

18-month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in DITRAME PLUS ANRS 1201/1202 2001-2005

HIV prevalence rates amongst 6 week old infants in South Africa: the case for universal screening at immunisation clinics

Maternal illness during pregnancy is associated with In utero mother to child transmission

Extensively drug resistant TB (XTB) in South Africa

XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006

Enough is enough: South African activists demand: fire Manto

Treatment access: more optimistic results from scale up programmes

Integrase inhibitor MK-0518: early results show greater early potency than efavirenz

Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect

Vicriviroc 24-week results in triple-class experienced R5-tropic patients

Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients

Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355

New data on darunavir (TMC-114)

Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance

Atazanavir/r monotherapy and CNS penetration

Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients

Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks

Children face a serious service delivery gap: paediatric studies in Toronto

Bioavailability study results for new paediatric tablets for oral suspension, and caution against splitting adult doses

Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) Trial

3TC/abacavir maintains virological superiority over AZT/3TC and AZT/abacavir beyond 5 years in children

French study raises importance of early screening for anal cancer in HIV-positive people

Prognostic index for risk of progression of Kaposi’s Sarcoma

Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

Selected abstracts from Track A presentations at Toronto

Use of complementary alternative medicine that could interact with ARV treatment reported by 20% patients in the UK

Poor scientific or medical knowledge is a factor in increase in criminal charges for HIV transmission in the UK

Treatment access and community responses: online webcasts and debates

15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain

Resistance implications of monotherapy with lopinavir/r (Kaletra)

Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir

Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients

Epidemiological studies and transmission of resistance: evidence for optimism – or issues with interpretation?

K103N containing variants persist longer in women with subtype D and with higher viral loads

No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine

Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women

Post navigation